 So we're hoping that rapamycin can target the underlying cause, which is aging, to improve patients that have periodontal disease. There's already some evidence from transplant patients that the drug may help improve oral health. And as part of the study, Ahn will also measure changes in participants' microbiomes and their biological clocks. The study will enroll participants over the age of 50 who have gum recession. They will take the drug for eight weeks.